Poolbeg Pharma partners with Eurofins to complete RNA sequencing

Poolbeg Pharma plc (LON:POLB), a clinical stage infectious disease pharmaceutical company with a capital light clinical model, has partnered with leading global biopharma services company, Eurofins Genomics, to complete RNA sequencing for Poolbeg of Respiratory Syncytial Virus disease progression samples from human viral challenge studies.

This deep sequencing work is a key step leading to Poolbeg commencing Artificial Intelligence (AI) analysis of its RSV data and will mean that it then has full immunological datasets for RSV, as well as influenza, which are ready to use with AI platforms to identify drug targets and products for influenza and RSV indications. The Company already has RNA sequencing data for influenza. This data is unique as it covers the full disease cycle and presents significant opportunities to unlock insights into these diseases which will magnify the power of the AI analysis.

The project with Eurofins is expected to be completed by the end of 2021 and will involve next generation RNA sequencing of RSV transcriptomics, or disease progression data, which enables the tracking of the biology of immune responses in molecular detail during infection.

Sequencing of the samples will be tailored for incorporation into AI algorithms which will be the first time that human challenge trial immune data has been analysed using AI, unlocking unique insights from the rich dataset that Poolbeg will translate into additional pipeline products which will be progressed using its capital light clinical structure.

RSV is a contagious virus that affects the respiratory tract of children and at-risk older adults; in severe cases, it can cause pneumonia and other life-threatening breathing difficulties. RSV is a significant public health threat and is one of the leading causes of hospitalisation to at-risk older adults. There is currently no vaccine on the market for RSV.

Jeremy Skillington, PhD, CEO of Poolbeg Pharma, said:

“This is an exciting step in our AI data analysis programme. The deep genetic analysis of RSV progression will be key information to feed into AI drug and target discovery tools. We already have similar data for influenza so we will now have complete discovery datasets for both influenza and RSV.

Our AI analysis will be breaking new ground in data-driven drug discovery as it will be the first time that human challenge trial immune data is used in this way. Having the sequencing specially tailored to work with AI platforms will enable us to discover potential new drug candidates for both diseases in a quicker and more cost-effective way.”

Click to view all articles for the EPIC:
Or click to view the full company profile:
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn

More articles like this

Poolbeg Pharma influenza AI model completed by CytoReason

Poolbeg Pharma plc (LON:POLB), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, has announced that, further to its announcement in March 2022, the construction of the computational artificial intelligence (AI) influenza disease model has been completed by

Poolbeg Pharma to host Capital Markets Day on 30 November

Poolbeg Pharma plc (LON:POLB, OTCQB: POLBF), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, has announced that it will be holding a Capital Markets Day for analysts and institutional investors on Wednesday 30

AI program yields multiple novel RSV drug targets

Poolbeg Pharma says it has made a breakthrough in its Artificial Intelligence (AI) program with partner OneThree Biotech, Inc. through the discovery of novel drug targets for the treatment of respiratory syncytial virus (RSV). Following the completion of

Cork and Dublin firms partner to develop oral vaccines

An infectious disease pharmaceutical company has joined forces with a specialist micro encapsulation company based in Cork to develop oral vaccines. Poolbeg Pharma based in Dublin has partnered with Carrigtwohill-based AnaBio to deliver oral vaccines. Poolbeg Pharma CEO

Poolbeg Pharma upbeat on US patent application progress

Infectious disease pharmaceutical company Poolbeg Pharma updated the market on its intellectual property (IP) position around ‘POLB 001’ on Tuesday, which it described as a small molecule immunomodulator for the treatment of severe influenza. The AIM-traded firm said the US

Poolbeg Pharma list of upcoming events

Poolbeg Pharma (LON:POLB, OTCQB: POLBF), a clinical stage infectious disease pharmaceutical company with a capital light clinical model, has announced that its management and business development team will be attending and presenting at a number upcoming partnering and investor

Poolbeg Pharma continues to expand global patent protection

Poolbeg Pharma PLC (LON:POLB, OTCQB: POLBF), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, has provided an update on the strengthening of its intellectual property (IP) position around POLB 001, a small molecule immunomodulator

2022 interim results: Financial & corporate highlights

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model. 

Poolbeg Pharma plc completes in-licence of Melioidosis vaccine candidate

Poolbeg Pharma plc (LON:POLB, OTCQB: POLBF, a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, announces that further to the Option Agreement announced in December 2021, Poolbeg has signed an exclusive Licence Agreement with University College

No more posts to show